guest ::
| Home > Publications database > Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. > print |
| Home > Publications database > Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. > print |
| 001 | 267545 | ||
| 005 | 20240229154920.0 | ||
| 024 | 7 | _ | |a 10.1186/s40478-023-01514-z |2 doi |
| 024 | 7 | _ | |a pmid:36759899 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9912509 |2 pmc |
| 024 | 7 | _ | |a altmetric:142359752 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00323 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pun, Matthew |b 0 |
| 245 | _ | _ | |a Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. |
| 260 | _ | _ | |a London |c 2023 |b Biomed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1676300907_32048 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Globally decreased histone 3, lysine 27 tri-methylation (H3K27me3) is a hallmark of H3K27-altered diffuse midline gliomas (DMGs) and group-A posterior fossa ependymomas (PFAs). H3K27-altered DMGs are largely characterized by lysine-to-methionine mutations in histone 3 at position 27 (H3K27M). Most PFAs overexpress EZH inhibitory protein (EZHIP), which possesses a region of similarity to the mutant H3K27M. Both H3K27M and EZHIP inhibit the function of the polycomb repressive complex 2 (PRC2) responsible for H3K27me3 deposition. These tumors often arise in neighboring regions of the brainstem and posterior fossa. In rare cases PFAs harbor H3K27M mutations, and DMGs overexpress EZHIP. These findings together raise the possibility that certain cell populations in the developing hindbrain/posterior fossa are especially sensitive to modulation of H3K27me3 states. We identified shared molecular features by comparing genomic, bulk transcriptomic, chromatin-based profiles, and single-cell RNA-sequencing (scRNA-seq) data from the two tumor classes. Our approach demonstrated that 1q gain, a key biomarker in PFAs, is prognostic in H3.1K27M, but not H3.3K27M gliomas. Conversely, Activin A Receptor Type 1 (ACVR1), which is associated with mutations in H3.1K27M gliomas, is overexpressed in a subset of PFAs with poor outcome. Despite diffuse H3K27me3 reduction, previous work shows that both tumors maintain genomic H3K27me3 deposition at select sites. We demonstrate heterogeneity in shared patterns of residual H3K27me3 for both tumors that largely segregated with inferred anatomic tumor origins and progenitor populations of tumor cells. In contrast, analysis of genes linked to H3K27 acetylation (H3K27ac)-marked enhancers showed higher expression in astrocytic-like tumor cells. Finally, common H3K27me3-marked genes mapped closely to expression patterns in the human developing hindbrain. Overall, our data demonstrate developmentally relevant molecular similarities between PFAs and H3K27M DMGs and support the overall hypothesis that deregulated mechanisms of hindbrain development are central to the biology of both tumors. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Brain development |2 Other |
| 650 | _ | 7 | |a Cancer |2 Other |
| 650 | _ | 7 | |a Chromatin biology |2 Other |
| 650 | _ | 7 | |a Neuro-oncology |2 Other |
| 650 | _ | 7 | |a Onco-histones |2 Other |
| 650 | _ | 7 | |a Pediatric tumors |2 Other |
| 650 | _ | 7 | |a Histones |2 NLM Chemicals |
| 650 | _ | 7 | |a Lysine |0 K3Z4F929H6 |2 NLM Chemicals |
| 650 | _ | 7 | |a Fluorocarbons |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Histones: genetics |2 MeSH |
| 650 | _ | 2 | |a Histones: metabolism |2 MeSH |
| 650 | _ | 2 | |a Lysine: genetics |2 MeSH |
| 650 | _ | 2 | |a Ependymoma: pathology |2 MeSH |
| 650 | _ | 2 | |a Glioma: genetics |2 MeSH |
| 650 | _ | 2 | |a Glioma: pathology |2 MeSH |
| 650 | _ | 2 | |a Rhombencephalon: pathology |2 MeSH |
| 650 | _ | 2 | |a Fluorocarbons |2 MeSH |
| 650 | _ | 2 | |a Mutation: genetics |2 MeSH |
| 650 | _ | 2 | |a Brain Neoplasms: genetics |2 MeSH |
| 650 | _ | 2 | |a Brain Neoplasms: pathology |2 MeSH |
| 700 | 1 | _ | |a Pratt, Drew |b 1 |
| 700 | 1 | _ | |a Nano, Patricia R |b 2 |
| 700 | 1 | _ | |a Joshi, Piyush K |0 P:(DE-He78)ee036c22158d4b18f5228616af640355 |b 3 |u dkfz |
| 700 | 1 | _ | |a Jiang, Li |b 4 |
| 700 | 1 | _ | |a Englinger, Bernhard |b 5 |
| 700 | 1 | _ | |a Rao, Arvind |b 6 |
| 700 | 1 | _ | |a Cieslik, Marcin |b 7 |
| 700 | 1 | _ | |a Chinnaiyan, Arul M |b 8 |
| 700 | 1 | _ | |a Aldape, Kenneth |b 9 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 10 |u dkfz |
| 700 | 1 | _ | |a Filbin, Mariella G |b 11 |
| 700 | 1 | _ | |a Bhaduri, Aparna |b 12 |
| 700 | 1 | _ | |a Venneti, Sriram |b 13 |
| 773 | _ | _ | |a 10.1186/s40478-023-01514-z |g Vol. 11, no. 1, p. 25 |0 PERI:(DE-600)2715589-4 |n 1 |p 25 |t Acta Neuropathologica Communications |v 11 |y 2023 |x 2051-5960 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:267545 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)ee036c22158d4b18f5228616af640355 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-09 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-09 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-09 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-09 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACTA NEUROPATHOL COM : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T09:09:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-26 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ACTA NEUROPATHOL COM : 2022 |d 2023-10-26 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|